Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT ID: NCT00391066
Last Updated: 2015-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
627 participants
INTERVENTIONAL
2006-11-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT00103558
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT00801060
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
NCT00090051
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT01082939
Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
NCT00206726
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
FCR
F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks
C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks
R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks
FCR
Dose, schedule, and duration specified in protocol
2
FCR + Lumiliximab (L)
L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.
F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks
C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks
R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks
FCR + Lumiliximab
Dose, schedule, and duration specified in the protocol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FCR + Lumiliximab
Dose, schedule, and duration specified in the protocol
FCR
Dose, schedule, and duration specified in protocol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of relapsed CD23+ and CD20+ B cell CLL as defined by NCI WG guidelines.
* Subjects who have received at least 1 but no more than 2 prior single agent or combination treatments for CLL.
* Rai Stage III or IV (Binet Stage C), or Rai Stage I or II (Binet Stage A or B) if determined to have disease progression as evidenced by rapid doubling of peripheral lymphocyte count, progressive lymphadenopathy, progressive splenomegaly, or B symptoms (Staging Criteria - Modified Rai).
* WHO Performance Status less than or equal to 2.
* Age greater than or equal to 18 years.
* Male and female subjects of reproductive potential must agree to follow accepted birth control methods during treatment and for 12 months after completion of treatment.
* Acceptable liver function: bilirubin less than or equal to 2.0 mg/dL (26 µmol/L); AST and ALT less than or equal to 2 times upper limit of normal.
* Acceptable hematologic status: platelet count greater than or equal to 50 x 10\^9/L should be unsupported by transfusion; ANC greater than or equal to 1 x 10\^9/L.
* Acceptable renal function: creatinine clearance calculated according to the formula of Cockcroft and Gault \>50 mL/min; serum creatinine less than or equal to 1.5 times upper limit of normal.
Exclusion Criteria
* Radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or other investigational therapy within 4 weeks prior to Study Day 1.
* Previous exposure to lumiliximab or other anti-CD23 antibodies.
* Prior autologous or allogeneic BMT or hematopoetic stem cell transplant.
* Known infection with HIV, hepatitis B, or hepatitis C. Although testing for hepatitis B or hepatitis C is not mandatory, this should be considered for all subjects considered at high risk of hepatitis B or hepatitis C infection and in endemic areas. Subjects with any serological evidence of current or past hepatitis B or hepatitis C exposure are excluded unless the serological findings are clearly due to vaccination.
* Uncontrolled diabetes mellitus.
* Uncontrolled hypertension.
* Transformation to aggressive B-cell malignancy (e.g., large B cell lymphoma, Richter's Syndrome, or PLL).
* Secondary malignancy requiring active treatment (except hormonal therapy).
* Any medical condition that would require long-term use (\>1 month) of systemic corticosteroids during study treatment. However, steroid use less than or equal to 1 month is permissible during the study.
* Any serious nonmalignant disease or laboratory abnormality, which in the opinion of the Investigator and/or Sponsor would compromise protocol objectives.
* Active uncontrolled bacterial, viral, or fungal infections.
* New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months prior to Study Day 1, unstable arrhythmia, or evidence of ischemia on ECG within 30 days prior to Study Day 1.
* Seizure disorders requiring anticonvulsant therapy.
* Severe chronic obstructive pulmonary disease with hypoxemia.
* Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1.
* Clinically active autoimmune disease.
* History of fludarabine-induced autoimmune cytopenia (as judged by the Investigator) or Coombs-positive haemolytic anemia.
* Pregnant or currently breastfeeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Scottsdale, Arizona, United States
Research Site
Alhambra, California, United States
Research Site
Burbank, California, United States
Research Site
Fullerton, California, United States
Research Site
La Jolla, California, United States
Research Site
Long Beach, California, United States
Research Site
Los Angeles, California, United States
Research Site
Northridge, California, United States
Research Site
Oxnard, California, United States
Research Site
Pomona, California, United States
Research Site
Redondo Beach, California, United States
Research Site
Sacramento, California, United States
Research Site
Santa Maria, California, United States
Research Site
Fort Myers, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Marietta, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Maywood, Illinois, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Overland Park, Kansas, United States
Research Site
Shreveport, Louisiana, United States
Research Site
Boston, Massachusetts, United States
Research Site
Detroit, Michigan, United States
Research Site
Saint Joseph, Michigan, United States
Research Site
Ypsilant,, Michigan, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Columbia, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Billings, Montana, United States
Research Site
Omaha, Nebraska, United States
Research Site
Hackensack, New Jersey, United States
Research Site
Morristown, New Jersey, United States
Research Site
Chapel Hill, North Carolina, United States
Research Site
Raleigh, North Carolina, United States
Research Site
Columbus, Ohio, United States
Research Site
Kettering, Ohio, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Greenville, South Carolina, United States
Research Site
Nashville, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Bedford, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Fort Worth, Texas, United States
Research Site
Fredericksburg, Texas, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Norfolk, Virginia, United States
Research Site
Roanoke, Virginia, United States
Research Site
Kennewick, Washington, United States
Research Site
Saint Louis, Washington, United States
Research Site
Spokane, Washington, United States
Research Site
Yakima, Washington, United States
Research Site
Córdoba, , Argentina
Research Site
Mendoza, , Argentina
Research Site
Darlinghurst, New South Wales, Australia
Research Site
Gosford, New South Wales, Australia
Research Site
St Leonards, New South Wales, Australia
Research Site
Waratah, New South Wales, Australia
Research Site
Westmead, New South Wales, Australia
Research Site
Greenslopes, Queensland, Australia
Research Site
Herston, Queensland, Australia
Research Site
South Brisbane, Queensland, Australia
Research Site
Woolloongabba, Queensland, Australia
Research Site
Adelaide, South Australia, Australia
Research Site
Adelaide, South Australia, Australia
Research Site
Ashford, South Australia, Australia
Research Site
Woodville, South Australia, Australia
Research Site
Box Hill, Victoria, Australia
Research Site
Clayton, Victoria, Australia
Research Site
Clayton, Victoria, Australia
Research Site
East Melbourne, Victoria, Australia
Research Site
Fitzroy, Victoria, Australia
Research Site
Freemantle, Western Australia, Australia
Research Site
Nedlands, Western Australia, Australia
Research Site
Perth, Western Australia, Australia
Research Site
Melbourne, , Australia
Research Site
Graz, , Austria
Research Site
Innsbruck, , Austria
Research Site
Salzburg, , Austria
Research Site
Vienna, , Austria
Research Site
Antwerp, , Belgium
Research Site
Bruges, , Belgium
Research Site
Brussels, , Belgium
Research Site
Edegem, , Belgium
Research Site
Ghent, , Belgium
Research Site
Herestraat, , Belgium
Research Site
Yvoir, , Belgium
Research Site
Goiania - GO, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
Santo André, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
London, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Hamilton, , Canada
Research Site
Québec, , Canada
Research Site
Brno, , Czechia
Research Site
Hradec Králové, , Czechia
Research Site
Prague, , Czechia
Research Site
Angers, , France
Research Site
Bordeaux, , France
Research Site
Le Mans, , France
Research Site
Lille, , France
Research Site
Limoges, , France
Research Site
Nantes, , France
Research Site
Nice, , France
Research Site
Pessac, , France
Research Site
Rennes, , France
Research Site
Rouen, , France
Research Site
Tours, , France
Research Site
Augsburg, , Germany
Research Site
Dessau, , Germany
Research Site
Frankfurt, , Germany
Research Site
Greifswald, , Germany
Research Site
Kiel, , Germany
Research Site
Würzburg, , Germany
Research Site
Athens, , Greece
Research Site
Heraklion, , Greece
Research Site
Ahmedabad, , India
Research Site
Bangalore, , India
Research Site
Delhi, , India
Research Site
Mumbai, , India
Research Site
Nashik, , India
Research Site
New Delhi, , India
Research Site
Pune, , India
Research Site
Trivandrum, , India
Research Site
Ashkelon, , Israel
Research Site
Haifa, , Israel
Research Site
Jerusalem, , Israel
Research Site
Petah Tikva, , Israel
Research Site
Ramat Gan, , Israel
Research Site
Rehovo, , Israel
Research Site
Milan, , Italy
Research Site
Novara, , Italy
Research Site
Roma, , Italy
Research Site
Rome, , Italy
Research Site
Rozzano, , Italy
Research Site
Verona, , Italy
Research Site
Klaipėda, , Lithuania
Research Site
Auckland, , New Zealand
Research Site
Christchurch, , New Zealand
Research Site
Hamilton, , New Zealand
Research Site
Palmerston North, , New Zealand
Research Site
Wellington, , New Zealand
Research Site
Bialystok, , Poland
Research Site
Gdansk, , Poland
Research Site
Katowice, , Poland
Research Site
Krakow, , Poland
Research Site
Lodz, , Poland
Research Site
Szczecin, , Poland
Research Site
Warsaw, , Poland
Research Site
Almada, , Portugal
Research Site
Braga, , Portugal
Research Site
Coimbra, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Porto, , Portugal
Research Site
Viseu, , Portugal
Research Site
Brasov, , Romania
Research Site
Bucharest, , Romania
Research Site
Iași, , Romania
Research Site
Nizhny Novgorod, , Russia
Research Site
Obninsk, , Russia
Research Site
Ryazan, , Russia
Research Site
Saint Peterburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Samara, , Russia
Research Site
Saratov, , Russia
Research Site
Yekaterinburg, , Russia
Research Site
Banská Bystrica, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Martin, , Slovakia
Research Site
Madrid, , Spain
Research Site
Murcia, , Spain
Research Site
Palma de Mallorca, , Spain
Research Site
Salamanca, , Spain
Research Site
Toledo, , Spain
Research Site
Zaragoza, , Spain
Research Site
Bath, , United Kingdom
Research Site
Belfast, , United Kingdom
Research Site
Birmingham, , United Kingdom
Research Site
Bournemouth, , United Kingdom
Research Site
Edinburgh, , United Kingdom
Research Site
Glasgow, , United Kingdom
Research Site
Leeds, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Plymouth, , United Kingdom
Research Site
Surrey, , United Kingdom
Research Site
Taunton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010 Jan 21;115(3):489-95. doi: 10.1182/blood-2009-08-237727. Epub 2009 Oct 20.
Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood. 2008 Feb 1;111(3):1594-602. doi: 10.1182/blood-2007-03-082024. Epub 2007 Nov 21.
Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55. doi: 10.1158/1078-0432.CCR-06-1463.
Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014 Nov;167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
152CL201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.